ABSTRACT
OBJECTIVE:To study and analyze the impact of rosuvastatin on function changes of endothelial cell. METHODS:30 patients with coronary heart disease were selected from our hospital during Jun. 2013 to Jun. 2014,and 15 healthy persons were included. They were divided into healthy control group,drug intervention of coronary heart disease group and coronary heart disease group with 15 cases in each group. The levels of asymmetric dimethylarginine (ADMA),NO and nitric oxide synthase (NOS) were determined by ELISA and compared among those groups. Its relationship with OD value was analyzed. After cultured for 4 h and 8 h,human umbilical vein endothelial cells (HUVEC) were divided into 5 groups,i.g. control group 0 μmol/L,0.1 μmol/L group,1 μmol/L group,10 μmol/L group,100 μmol/L group. The change of DDAH mRNA expression in endothelial cells treated with different concentrations of rosuvastatin was detected. RESULTS:The level of ADMA in drug intervention of coronary heart disease group were significantly lower than in coronary heart disease group,but still higher than that in healthy control group;NO and NOS levels were significantly higher than coronary heart disease group,but still lower than healthy control group,with statisti-cal significance (P<0.05). According to Pearson method correlation analysis,OD value was positively correlated to ADMA,NO and NOS. 4h after HUVEC culture,RT-PCR showed that mRNA expression of DDAH were increased in 0.1 μmol/L,1 μmol/L, 10μmol/L and 100μmol/L rosuvastatin groups,there was statistically significant difference between 10μmol/L and 100μmol/L ro-suvastatin groups and control group (P<0.05). 8 h after HUVEC culture,RT-PCR showed mRNA expression of DDAH were in-creased in 0.1 μmol/L,1 μmol/L,10 μmol/L and 100 μmol/L rosuvastatin groups,and there was statistically significant difference between 10 μmol/L rosuvastatin group and control group(P<0.05). CONCLUSIONS:Rosuvastatin is a new type of lipid-lowering drugs,which has a good protective effect on endothelial cells,it is worthy of attention in the clinic.
ABSTRACT
Objective To investigate the changes of plasma bone morphogenetic protein-4 (BMP-4) levels in patients with coronary heart disease (CHD) and rosuvastatin intervention effect on BMP-4 level.Methods Fifty-two patients with CHD and 35 health people were enrolled in this study as CHD group and control group.ELISA method was used to detect the concentration of plasma BMP-4.Analyzed the relationship between plasma BMP-4 and blood lipids,flow-mediated dilation (FMD),nitric oxide (NO),cyclooxygenase-2 (COX-2),malondialdehyde (MDA) and superoxide dismutase (SOD).And observed the changing of plasma BMP-4 before and after rosuvastatin intervention.Results Plasma BMP-4 level in CHD patients was (7.53 ± 1.20) μg/L,higher than that of control group ((3.81 ± 0.79) μ g/L,t =3.541,P =0.006).After rosuvastatin treatment,plasma BMP-4 level in CHD patient was decreased from (7.53 ± 1.20) μg/L to (5.40± 0.98) μg/L (t =1.436,P =0.001).Plasma BMP-4 level was positively correlated with COX-2,MDA,low-density lipoprotein cholesterol,total cholesterol (r =0.395,0.350,0.274,0.288 respectively,P ＜ 0.01 or P ＜0.05).But,it was negatively correlated with NO,high-density lipoprotein cholesterol,SOD,FMD (r =-0.291,-0.253,-0.476,-0.320 respectively,P ＜0.01 or P ＜0.05).COX-2,SOD and FMD were independent risk factors of plasma BMP-4 in patients with CHD.Conclusion Oxidative stress and endothelial dysfunction are in patients with CHD.Rosuvastatin treatment can remarkably reduce plasma BMP-4 level,alleviate vascular endothelium injury induced by oxidative stress and improve endothelial function in patients with CHD.